Skip to main content
Clinical Trials/NCT02389673
NCT02389673
Recruiting
Not Applicable

Intra-operative Radiotherapy After Breast-conversing Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer

Liao Ning1 site in 1 country222 target enrollmentOctober 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Liao Ning
Enrollment
222
Locations
1
Primary Endpoint
ipsilateral breast tumor recurrence rate after surgery within five years
Status
Recruiting
Last Updated
11 years ago

Overview

Brief Summary

Whether the patients with low grade ductal carcinoma in situ breast cancer should accept radiationtherapy is uncertain.Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to find out the effectiveness of radiation therapy during surgery in treating women who have undergone breast-conversing surgery for low grade ductal carcinoma in situ breast cancer.

Detailed Description

Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to find out the effectiveness of radiation therapy during surgery in treating women who have undergone breast-conversing surgery for low grade ductal carcinoma in situ breast cancer.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
June 2026
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Liao Ning
Responsible Party
Sponsor Investigator
Principal Investigator

Liao Ning

Guangdong Academy of Medical Sciences

Guangdong Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Tumor diameter \< 5 cm
  • Low grade ductal carcinoma in situ
  • Candidate for breast-conserving surgery
  • Must have undergone lumpectomy with negative margins or minimal margin involvement
  • Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection
  • No evidence of metastatic disease
  • Informed consent

Exclusion Criteria

  • No informed consent
  • Tumor size \> 5 cm
  • Intermediate or high grade ductal carcinoma in situ
  • Invasive carcinoma
  • No indication for a boost

Outcomes

Primary Outcomes

ipsilateral breast tumor recurrence rate after surgery within five years

Time Frame: Within 5 years after surgery

Within 5 years after surgery,we should evaluate ipsilateral breast tumor recurrence and Disease free survival as the most important outcome measure

Secondary Outcomes

  • Disease free survival after surgery within five years(Within 5 years after surgery)
  • Overall survival after surgery within ten years(Within ten years after surgery)

Study Sites (1)

Loading locations...

Similar Trials